文献速递脑血管病

低剂量与标准剂量阿替普酶在急性腔隙性缺血性卒中中的比较:ENCHANTED试验

Low-Dose vs Standard-Dose Alteplase in Acute Lacunar Ischemic Stroke: The ENCHANTED Trial.
PubMed 文献 · Neurology · 2021-02-03

该研究为ENCHANTED试验阿替普酶剂量臂的事后分析,纳入2588例有影像和临床数据的急性缺血性卒中患者,分为明确/ probable腔隙性(n=490)和非腔隙性(n=2098)。结果显示,无论接受何种剂量阿替普酶,腔隙性卒中患者的功能结局(mRS 2-6)优于非腔隙性(aOR 0.60, 95%CI 0.47-0.77);低剂量与标准剂量在腔隙性 vs 非腔隙性卒中之间对所有结局均无差异交互作用(所有p交互≥0.07)。结论认为低剂量阿替普酶对明确/probable腔隙性卒中并无优于标准剂量的证据。

要点

  • 腔隙性卒中患者功能结局优于非腔隙性(mRS 2-6 aOR 0.60)。
  • 低剂量与标准剂量阿替普酶对功能结局无差异(mRS 2-6 aOR 1.04)。
  • 低剂量与标准剂量在腔隙性 vs 非腔隙性卒中间无差异疗效(p交互≥0.07)。

核心结论

  • ENCHANTED试验未发现低剂量阿替普酶对明确/probable腔隙性急性缺血性卒中具有优于标准剂量的优势。

研究设计与样本

  • ENCHANTED试验阿替普酶剂量臂的事后分析,共3297例参与者,其中2588例有影像和临床数据用于主要分析。
  • 按预设定义将患者分为明确/probable腔隙性(n=490)和非腔隙性(n=2098)急性缺血性卒中。
  • 采用logistic回归模型分析腔隙性卒中与90天结局的关联及低剂量与标准剂量阿替普酶的治疗效应,并校正基线协变量。

主要发现

  • 腔隙性卒中患者较非腔隙性患者功能结局更优(mRS 2-6,校正OR 0.60,95%CI 0.47-0.77)。
  • 低剂量与标准剂量阿替普酶对功能结局(mRS 2-6)无差异效应(OR 1.04,95%CI 0.87-1.24)。
  • 低剂量阿替普酶降低了所有纳入患者症状性颅内出血的风险。
  • 低剂量与标准剂量阿替普酶在腔隙性与非腔隙性卒中亚组间对所有结局均无差异治疗效应(所有p交互≥0.07)。

关键数值与推荐

  • 主要结局为90天mRS评分2-6。
  • 次要结局包括其他mRS评分、颅内出血和早期神经功能恶化或死亡。
  • 低剂量与标准剂量阿替普酶在腔隙性与非腔隙性卒中亚组间的交互作用所有p≥0.07。

临床怎么用

  • 对于明确/probable腔隙性急性缺血性卒中,低剂量阿替普酶未显示额外获益或安全性优势,不支持常规使用低剂量替代标准剂量。

局限性

  • 本研究为ENCHANTED试验的事后分析。
  • 仅2588例参与者有可用影像和临床数据用于主要分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine any differential efficacy and safety of low- vs standard-dose IV alteplase for lacunar vs nonlacunar acute ischemic stroke (AIS), we performed post hoc analyzes from the Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED) alteplase dose arm. METHODS: In a cohort of 3,297 ENCHANTED participants, we identified those with lacunar or nonlacunar AIS with different levels of confidence (definite/according to prespecified definitions based on clinical and adjudicated imaging findings. Logistic regression models were used to determine associations of lacunar AIS with 90-day outcomes (primary, modified Rankin Scale [mRS] scores 2-6; secondary, other mRS scores, intracerebral hemorrhage [ICH], and early neurologic deterioration or death) and treatment effects of low- vs standard-dose alteplase across lacunar and nonlacunar AIS with adjustment for baseline covariables. RESULTS: Of 2,588 participants with available imaging and clinical data, we classified cases as definite/probable lacunar (n = 490) or nonlacunar AIS (n = 2,098) for primary analyses. Regardless of alteplase dose received, lacunar AIS participants had favorable functional (mRS 2-6, adjusted odds ratio [95% confidence interval] 0.60 [0.47-0.77]) and other clinical or safety outcomes compared to participants with nonlacunar AIS. Low-dose alteplase (versus standard) had no differential effect on functional outcomes (mRS 2-6, 1.04 [0.87-1.24]) but reduced the risk of symptomatic ICH in all included participants. There were no differential treatment effects of low- vs standard-dose alteplase on all outcomes across lacunar and nonlacunar AIS (all p interaction ≥0.07). CONCLUSIONS: We found no evidence from the ENCHANTED trial that low-dose alteplase had any advantages over standard dose for definite/probable lacunar AIS. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with lacunar AIS, low-dose alteplase had no additional benefit or safety over standard-dose alteplase. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov identifier NCT01422616.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Zhou Z, Delcourt C, Xia C, et al. Low-Dose vs Standard-Dose Alteplase in Acute Lacunar Ischemic Stroke: The ENCHANTED Trial. Neurology. 2021. PMID: 33536271. doi:10.1212/WNL.0000000000011598

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。